Abstract: A device that allows for either fat graft preparation or cell fraction harvest is disclosed. The device includes a first centrifuge tube configured to receive and process a biological substance, the first centrifuge tube comprising an upper cylindrical portion and a lower conical portion, a sterile tissue inlet fitting, at least one sterile processing fluid inlet fitting, a sterile suction fitting, and at least one sterile extraction port connected to a first extraction tube. The first centrifuge tube further includes an internal space including a screen being positioned therein, the screen being configured to divide the internal space in half, and a filter positioned therein, the filter being positioned below the screen in the lower conical portion of the first centrifuge tube. The device may further include a second centrifuge tube configured to receive and further process the biological substance from the first centrifuge tube.

Abstract: Provided herein are methods and compositions for treatment of Batten disease. Such compositions include a recombinant adeno-associated virus (rAAV), said rAAV comprising an AAV capsid, and a vector genome packaged therein, said vector genome comprising (a) an AAV inverted terminal repeat (ITR) sequence; (b) a promoter; (c) a CLN2 coding sequence encoding a human TPP1; (d) an AAV 3? ITR.

Abstract: I/O network modules connect field devices to a process control network. Each I/O network module includes a set of electrical connectors for connecting a field device to the module and an I/O channel extending from the set of electrical connectors to a network port. The I/O channel includes a conversion circuit that converts between an I/O signal and network-compatible signals. Each I/O channel connected to the process control network through an I/O network module is associated with its own unique network address. This enables controllers and field devices on the process control network to communicate essentially directly with one another through the network.

Abstract: A device that allows for either fat graft preparation or cell fraction harvest is disclosed. The device includes a first centrifuge tube configured to receive and process a biological substance, the first centrifuge tube comprising an upper cylindrical portion and a lower conical portion, a sterile tissue inlet fitting, at least one sterile processing fluid inlet fitting, a sterile suction fitting, and at least one sterile extraction port connected to a first extraction tube. The first centrifuge tube further includes an internal space including a screen being positioned therein, the screen being configured to divide the internal space in half, and a filter positioned therein, the filter being positioned below the screen in the lower conical portion of the first centrifuge tube. The device may further include a second centrifuge tube configured to receive and further process the biological substance from the first centrifuge tube.

Abstract: Provided herein is a recombinant AAV (rAAV) comprising an AAV capsid and a vector genome packaged therein, wherein the vector genome comprises an AAV 5? inverted terminal repeat (ITR), an engineered nucleic acid sequence encoding a functional hSGSH, a regulatory sequence which direct expression of hSGSH in a target cell, and an AAV 3? ITR. Also provided is a pharmaceutical composition comprising a rAAV as described herein in a formulation buffer, and a method of treating a human subject diagnosed with MPS IIIA.

Abstract: A rAAV vector is described herein which has an AAVhu68 capsid and at least one expression cassette in the capsid. The at least one expression cassette comprises nucleic acid sequences encoding a functional SMN protein and expression control sequences that direct expression of the SMN sequences in a host cell. Also provided are compositions containing this rAAVhu68.SMN vector and methods of using same for spinal muscular atrophy in a patient.

Abstract: A pharmaceutical composition formulated for delivery of a recombinant adeno-associated virus (rAAV) vector comprising an AAV capsid and a vector genome having human galactosylceramidase (GALC) coding sequence is provided. Also provided are 5 methods and uses of a pharmaceutical composition comprising a rAAV for the treatment of Krabbe disease.

Abstract: A therapeutic regimen useful for treatment of GM1 gangliosidosis comprising administration of a recombinant adeno-associated virus (rAAV) vector having an AAV capsid and a vector genome comprising a sequence encoding human ?-galactosidase is provided. Also provided are compositions containing a rAAV vector and methods of treating GM1 gangliosidosis in patient comprising administration of a rAAV vector.

Abstract: I/O network modules connect field devices to a process control network. Each I/O network module includes a set of electrical connectors for connecting a field device to the module and an I/O channel extending from the set of electrical connectors to a network port. The I/O channel includes a conversion circuit that converts between an I/O signal and network-compatible signals. Each I/O channel connected to the process control network through an I/O network module is associated with its own unique network address. This enables controllers and field devices on the process control network to communicate essentially directly with one another through the network.

Abstract: Provided herein are methods and compositions for treatment of Batten disease. Such compositions include a recombinant adeno-associated virus (rAAV), said rAAV comprising an AAV capsid, and a vector genome packaged therein, said vector genome comprising (a) an AAV 5? inverted terminal repeat (ITR) sequence; (b) a promoter; (c) a CLN2 coding sequence encoding a human TPP1; (d) an AAV 3? ITR.

Abstract: A rAAV vector is described herein which has an AAVhu68 capsid and at least one expression cassette in the capsid. The at least one expression cassette comprises nucleic acid sequences encoding a functional SMN protein and expression control sequences that direct expression of the SMN sequences in a host cell. Also provided are compositions containing this rAAVhu68.SMN vector and methods of using same for spinal muscular atrophy in a patient.

Abstract: A recombinant adeno-associated virus (rAAV) comprising an AAVhu68 capsid and a vector genome comprising a lysosomal beta-galactosidase gene (for example, galactosidase beta 1 gene, GBL1) is provided (i.e., rAAVhu68.GBL1). Also provided a composition containing an effective amount of rAAVhu68.GBL1 to ameliorate symptoms of GM1 gangliosidosis, including, e.g., increased average life span, decreased need for feeding tube, reduction in seizure incidence and frequency, reduction in progression towards neurocognitive decline and/or improvement in neurocognitive development.

Abstract: Provided herein is a recombinant AAV (rAAV) comprising an AAV capsid and a vector genome packaged therein, wherein the vector genome comprises an AAV 5? inverted terminal repeat (ITR), an engineered nucleic acid sequence encoding a functional hSGSH, a regulatory sequence which direct expression of hSGSH in a target cell, and an AAV 3? ITR. Also provided is a pharmaceutical composition comprising a rAAV as described herein in a formulation buffer, and a method of treating a human subject diagnosed with MPS IIIA.

Abstract: I/O network modules connect field devices to a process control network. Each I/O network module includes a set of electrical connectors for connecting a field device to the module and an I/O channel extending from the set of electrical connectors to a network port. The I/O channel includes a conversion circuit that converts between an I/O signal and network-compatible signals. Each I/O channel connected to the process control network through an I/O network module is associated with its own unique network address. This enables controllers and field devices on the process control network to communicate essentially directly with one another through the network.

Abstract: A therapeutic composition comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in a three-dimensional biocompatible gel matrix, and methods, and systems for preparing and using encapsulated adipose-derived mesenchymal stem cells. Hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The gel matrix allows the release of cellular factors from the encapsulated stem cells to surrounding tissues to achieve desired therapeutic results.

Abstract: A composition formulated for intrathecal delivery of a recombinant adeno-associated virus (rAAV) vector comprising an AAVhu68 capsid carrying a human galactosylceramidase (GALC) gene for administration to Krabbe patients is provided. Also provided are novel gene sequences and uses thereof.

Abstract: A field device I/O connector includes a base and an I/O module removably mounted on the base for transmitting I/O signals along an I/O channel. A set of electrical connectors mounted on the base connect the base to a field device. The electrical connectors, the base, and the I/O module mounted on the base cooperate to define the I/O channel. The I/O channel includes a conversion circuit to convert between I/O signals and a digital data format output from the field device I/O connector. The base and I/O module also cooperate to define a diagnostic circuit connected to the portion of the I/O channel extending through the I/O module. The diagnostic circuit extends to a diagnostic logic circuit that may be included on the base, in the I/O module, or away from the field device I/O connector.

Abstract: I/O network modules connect field devices to a process control network. Each I/O network module includes a set of electrical connectors for connecting a field device to the module and an I/O channel extending from the set of electrical connectors to a network port. The I/O channel includes a conversion circuit that converts between an I/O signal and network-compatible signals. Each I/O channel connected to the process control network through an I/O network module is associated with its own unique network address. This enables controllers and field devices on the process control network to communicate essentially directly with one another through the network.

Abstract: A field device I/O connector includes a base and an I/O module removably mounted on the base for transmitting I/O signals along an I/O channel. A set of electrical connectors mounted on the base connect the base to a field device. The electrical connectors, the base, and the I/O module mounted on the base cooperate to define the I/O channel. The I/O channel includes a conversion circuit to convert between I/O signals and a digital data format output from the field device I/O connector. The base and I/O module also cooperate to define a diagnostic circuit connected to the portion of the I/O channel extending through the I/O module. The diagnostic circuit extends to a diagnostic logic circuit that may be included on the base, in the I/O module, or away from the field device I/O connector.

Abstract: A device that allows for either fat graft preparation or cell fraction harvest is disclosed. The device includes a first centrifuge tube configured to receive and process a biological substance, the first centrifuge tube comprising an upper cylindrical portion and a lower conical portion, a sterile tissue inlet fitting, at least one sterile processing fluid inlet fitting, a sterile suction fitting, and at least one sterile extraction port connected to a first extraction tube. The first centrifuge tube further includes an internal space including a screen being positioned therein, the screen being configured to divide the internal space in half, and a filter positioned therein, the filter being positioned below the screen in the lower conical portion of the first centrifuge tube. The device may further include a second centrifuge tube configured to receive and further process the biological substance from the first centrifuge tube.